Dual-Composition Dry Eye Kit for Chronic and Acute Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye disease are inadequate in addressing both chronic conditions and episodic flare-ups, often providing insufficient relief and varying in effectiveness from day to day.
Innovation Solution
A pharmaceutical kit comprising two compositions: a first composition with a corticosteroid and/or immunosuppressant for chronic dry eye disease treatment, and a second composition with a higher corticosteroid concentration or different corticosteroid for acute episodic flare-ups, along with a pharmaceutical-free lubricating formulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If a single composition is used for treating dry eye disease, then the treatment is simple, but it cannot effectively address both chronic conditions and episodic flare-ups
Solution Approach 1:
The treatment is divided into two separate compositions: a first composition containing an immunosuppressant for chronic dry eye disease management, and a second composition containing a corticosteroid for acute flare-up treatment. This segmentation allows each composition to target specific aspects of the disease, improving overall treatment effectiveness while maintaining clear differentiation of purposes.
Solution Approach 2:
The kit combines multiple therapeutic agents (immunosuppressant and corticosteroid) into a single integrated system that addresses both chronic and acute phases of dry eye disease. This multi-functional approach enables the kit to provide comprehensive treatment coverage for varying disease states without requiring separate treatment regimens.
2Reliability
If higher corticosteroid concentration is used for acute flare-ups, then symptom relief is improved, but the risk of side effects increases
Solution Approach 1:
The treatment regimen is made dynamic by allowing adjustment of corticosteroid dosage based on disease activity. During acute flare-ups, higher concentrations of the second composition can be administered for rapid symptom relief, while during stable chronic phases, the first composition with immunosuppressant is used at lower, maintenance doses. This dynamic dosing strategy optimizes symptom relief while minimizing cumulative side effects.
Solution Approach 2:
The kit enables partial action by using the corticosteroid-containing second composition selectively during acute flare-ups rather than continuously. This targeted approach applies the stronger medication only when needed for excessive symptom relief, avoiding unnecessary exposure and reducing the risk of side effects during stable periods.
3Reliability
If multiple compositions are used to address different disease phases, then treatment effectiveness is improved, but the complexity of administration increases
Solution Approach 1:
The kit packaging serves as an intermediary organization system that clearly separates the two compositions and provides structured administration guidelines. By pre-organizing the immunosuppressant and corticosteroid compositions in distinct containers with labeled instructions, the kit mediates between the complexity of dual-therapy requirements and the simplicity of patient self-administration, making it easier to follow the differentiated treatment protocol.
Data Source
AI summary
Pharmaceutical kits and use of the kits in the treatment of conditions of the eye, such as dry eye disease, which includes a first composition including a corticosteroid, an immunosuppressant or both a corticosteroid and an immunosuppressant in a pharmaceutically acceptable carrier configured for administration to a subject’s eyes; a second composition including a corticosteroid in a pharmaceutically acceptable carrier configured for administration to a subject’s eyes, where the second composition has a higher concentration of corticosteroid than the first composition; and optionally a lubricating formulation that is pharmaceutical-free. Treatment of dry eye disease includes administering topically to the eyes of a subject suffering from chronic dry eye disease the first composition over a treatment period; and if the subject suffers from an episodic flare up during the treatment period, administering the second composition to substantially alleviate the flare-up.